The European Medicines Agency (EMA) Thursday recommended authorising the COVID-19 vaccine Bimervax (previously COVID-19 Vaccine HIPRA) as a booster in people aged 16 years and above who have been vaccinated with an mRNA COVID-19 vaccine.

Bimervax, developed by HIPRA Human Health, a multinational company based in Spain, contains a protein produced in the laboratory that consists of part of the SARS-CoV-2 spike protein from the Alpha and Beta virus variants, it said in a press release.

EMA concluded that a booster dose of Bimervax is expected to be at least as effective as Comirnaty at restoring protection against COVID-19 in people aged 16 years and older It added that the benefits of Bimervax outweigh its risks and recommended granting a standard marketing authorisation in the EU.

Source: Kuwait News Agency